Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Apr 6, 2015 Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology
Apr 6, 2015 Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma
What's New

2012 Form 10-K

More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 5, 2014 Form 10-Q View HTML View PDF 559.6 KB Add to Briefcase
Feb 24, 2015 Form 10-K View HTML View PDF 1.1 MB Add to Briefcase
Add to Briefcase = add file to Briefcase